| Followers | 39 |
| Posts | 2870 |
| Boards Moderated | 0 |
| Alias Born | 12/06/2003 |
Friday, December 15, 2017 7:44:34 PM
I'm more curious about AT-014
As I see it that is a bureaucratic disgrace that the osteosarcoma vaccine has not already been fully approved while even now it is fighting for only a qualified license after an added test.
The osteosarcoma vaccine is a therapeutic cancer vaccine that had fallen into a rathole as a blacklisted human cancer vaccine so that the owner had various makebelieve names for its human development and it got assigned to the Agriculture Department by the veterinary bureaucracy. The Ag boys don't know from nothing about a therapeutic vaccine. They are quite familiar with routine prophylactic vaccines.
Not that I would ever want to say any mean things about bureaucrats which I once was.
PETX and ADXS [the owner of the osteosarcoma vaccine] have wasted a lot of energy yelling at each other because they can't yell at the regulators who hold them by the throat.
Best, Terry
As I see it that is a bureaucratic disgrace that the osteosarcoma vaccine has not already been fully approved while even now it is fighting for only a qualified license after an added test.
The osteosarcoma vaccine is a therapeutic cancer vaccine that had fallen into a rathole as a blacklisted human cancer vaccine so that the owner had various makebelieve names for its human development and it got assigned to the Agriculture Department by the veterinary bureaucracy. The Ag boys don't know from nothing about a therapeutic vaccine. They are quite familiar with routine prophylactic vaccines.
Not that I would ever want to say any mean things about bureaucrats which I once was.
PETX and ADXS [the owner of the osteosarcoma vaccine] have wasted a lot of energy yelling at each other because they can't yell at the regulators who hold them by the throat.
Best, Terry
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
